Pliant Therapeutics Appoints Suzanne Bruhn, Ph.D., To Board Of Directors
2016-08-30
合作免疫疗法
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pliant
Therapeutics, Inc., a company focused on discovering, developing and
commercializing breakthrough treatments for fibrotic diseases, today
announced the appointment of Suzanne Bruhn, Ph.D., to its board of
directors.
“With a career spanning almost two decades of success in
the development, commercialization and partnering of new therapies for
patients, her breadth of experience will bring significant value to
Pliant Therapeutics as we advance our pipeline of innovative fibrosis
therapies.”
“Suzanne is a distinguished biopharmaceutical leader who brings a wealth
of drug development expertise, and in particular, a deep knowledge of
the fibrosis field,” said Bernard Coulie, M.D., Ph.D., CEO of Pliant
Therapeutics. “With a career spanning almost two decades of success in
the development, commercialization and partnering of new therapies for
patients, her breadth of experience will bring significant value to
Pliant Therapeutics as we advance our pipeline of innovative fibrosis
therapies.”
Dr. Bruhn most recently served as president and CEO of Promedior, Inc.,
a privately held, clinical-stage immunotherapy company pioneering the
development of targeted therapeutics to treat diseases involving
fibrosis. There, she successfully negotiated an exclusive agreement with
Bristol Myers Squibb for the right to acquire Promedior for a total deal
potential of $1.25 billion. Prior to Promedior, Dr. Bruhn spent 13 years
at Shire Human Genetic Therapies (HGT), a division of Shire PLC, where
she held a series of positions of increasing responsibility before
serving as senior vice president of strategic planning and program
management. Currently, Dr. Bruhn serves on the board of directors of
Raptor Pharmaceuticals (NASDAQ: RPTP), a commercial-stage,
biopharmaceutical company developing therapeutics for orphan diseases.
Dr. Bruhn received a Bachelor’s degree from Iowa State University, a
Ph.D. from the Massachusetts Institute of Technology and was a
postdoctoral fellow at Harvard Medical School.
“While significant medical and scientific progress has been made in
recent years, there is still much work to be done for patients with
fibrotic diseases,” said Dr. Bruhn. “Pliant Therapeutics truly embraces
the challenge of developing new therapies for fibrosis, and I am looking
forward to contributing my understanding of clinical development as the
company advances its therapeutic pipeline.”
About Pliant Therapeutics
Pliant Therapeutics is an early-stage biotechnology company harnessing
the therapeutic capabilities of integrin biology and TGF-ß signaling to
develop breakthrough treatments for fibrotic diseases. By leveraging its
powerful product engine, Pliant’s mission is to prevent or even reverse
fibrosis, restoring organ function. The company also aims to build a
patient registry for certain areas of fibrotic disease to both increase
understanding of natural disease progression and fuel biomarker
discovery for efficient clinical trial design. Founded by a group of
seasoned experts in fibrosis biology and medicinal chemistry, Pliant
Therapeutics was launched in 2016 by Third Rock Ventures and is
headquartered in Redwood City, California. For more information, please
visit .
Contacts
Pure CommunicationsKatie Engleman, 910-509-3977Katie@purecommunicationsinc.com
药物
-热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。